Related Experiment Video
Updated: Mar 24, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments
Matthias Naegele1, Andreas J Flammer1, Frank Enseleit1
1University Heart Centre, Cardiology, University Hospital Zurich, Switzerland.
Abstract:
Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition with a significant individual and societal burden. Although it was previously known as a palliative condition, medical drug therapies that were developed in the last four decades significantly reduced morbidity and mortality of the disease. The cornerstone of HFrEF therapy remains the blockade of the renin-angiotensin-aldosterone and the β-adrenergic systems. This review aims to give an overview and update on established disease-modifying therapies in HFrEF, discuss advances and setbacks in the treatment of selected comorbidities and provide an outlook on upcoming therapies including the new concept of dual angiotensin receptor and neprilysin inhibition.
More Related Videos
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Cardiomyopathy V: Interprofessional Care
Heart Failure IV: Classification and Diagnostic Evaluation